Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | RXRB | P28702 | 2/20 | 0.55 |
| ▸ | RXRG | P48443 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437991 | 0.87 | RXRA (0.61) | RXRARXRBRXRGMAOBMRGPRX4 | |
| SCHEMBL2947608 | 0.84 | RXRA (0.57) | RXRARXRBRXRGMAOBMRGPRX4 | |
| SCHEMBL6054391 | 0.82 | RXRA (0.60) | RXRARXRBRXRGMAOBMRGPRX4 | |
| SCHEMBL30440465 | 0.79 | CREBBP (0.60) | RXRARXRBRXRGMAOBMAOA | |
| SCHEMBL314656 | 0.79 | CREBBP (0.60) | RXRARXRBRXRGMAOBMAOA | |
| SCHEMBL313614 | 0.79 | CYP2C9 (0.48) | RXRARXRBRXRGMAOBMAOA | |
| SCHEMBL6054444 | 0.78 | MRGPRX4 (0.57) | RXRARXRBRXRGMAOBMRGPRX4 | |
| SCHEMBL2146375 | 0.77 | CYP3A4 (0.51) | RXRARXRBRXRGMRGPRX4CTSS | |
| SCHEMBL10323654 | 0.77 | RXRA (0.45) | RXRARXRBRXRGMAOBMRGPRX4 | |
| SCHEMBL17386686 | 0.77 | THRA (0.56) | RXRARXRBRXRGMAOBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2176223-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | RXRA 4013/4885RXRB 4472/4885RXRG 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.